Research programme: interleukin-1 receptor associated kinase inhibitors - Rigel Pharmaceuticals

Drug Profile

Research programme: interleukin-1 receptor associated kinase inhibitors - Rigel Pharmaceuticals

Alternative Names: IRAK4 kinase inhibitors - Rigel Pharmaceuticals; R 191

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 07 Oct 2016 Rigel Pharmaceuticals announces intention to file an IND application with the US FDA in 2017
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Haematological malignancies presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 13 Apr 2016 Preclinical trials in Haematological malignancies in USA (unspecified route) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top